Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen Inc    BIIB

BIOGEN INC (BIIB)

Delayed Quote. Delayed  - 07/27 07:07:14 pm
287.71 USD   +0.23%
07/22DJGEORGE SCANGOS : Biogen CEO Scangos to Step Down -- WSJ
07/21 Joy Global and Biogen climb; Intel and Union Pacific slide
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Biogen Idec Inc. : Biogen 4th-Quarter Profit Falls 2.7% on Higher Costs; Revenue Up

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/28/2013 | 01:13pm CEST
   By Tess Stynes and Melodie Warner 
 

Biogen Idec Inc.'s (BIIB) fourth-quarter earnings fell 2.7% as the biotechnology company's efforts to bulk up its product pipeline masked its revenue growth.

The company also forecast 2013 adjusted earnings of $7.15 to $7.25 a share on about 10% revenue growth. Analysts surveyed by Thomson Reuters expect $7.27 a share on a 9% rise in revenue to $5.98 billion.

Biogen on Thursday said a new version of its blockbuster multiple-sclerosis drug Avonex was successful in a late-stage trial, strengthening the company's stable of drugs for the degenerative nerve disease. However, the overall market for such injectable drugs is expected to decline sharply amid a growing market for oral-pill-based drugs. Biogen's own BG-12 pill could be approved and launched in the U.S. as soon as March.

Biogen has been beefing up its sales force and readying its manufacturing supply chain as some drugs in its late-stage product pipeline have been drawing closer to entering the market.

Research and development costs rose 1.8% in the latest period while selling, general and administrative costs jumped 32%.

Biogen reported a profit of $292.1 million, or $1.23 a share, down from $300.2 million, or $1.22 a share, a year earlier. Excluding items such as stock-option expense, amortization and restructuring charges, per-share earnings fell to $1.40 from $1.51. Revenue increased 6.9% to $1.42 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.46 a share on revenue of $1.39 billion.

In the latest quarter, sales of Avonex rose 7.1% to $753.2 million.

Shares closed Friday at $146.20 and were inactive premarket. The stock is up 23% over the past year.

Write to Tess Stynes at tess.stynes@dowjones.com and Melodie Warner at melodie.warner@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOGEN INC
07/22DJGEORGE SCANGOS : Biogen CEO Scangos to Step Down -- WSJ
07/21 BIOGEN : Management's Discussion and Analysis of Financial Condition and Results..
07/21 Joy Global and Biogen climb; Intel and Union Pacific slide
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
07/21DJBIOGEN : CEO to Step Down; Reports Upbeat Earnings, Outlook--Update
07/21DJBIOGEN : CEO to Step Down; Reports Upbeat Earnings, Outlook
07/21 BIOGEN : rises after 2nd-quarter results surpass forecasts
07/21 BIOGEN INC. : Results of Operations and Financial Condition (form 8-K)
07/21 BIOGEN : Reports Second Quarter 2016 Revenues of $2.9 Billion
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance
More news
Sector news : Specialty & Advanced Pharmaceuticals
07:11pDJPFIZER : Cleared to Buy Nanotech Drug Firm Bind Therapeutics
07:02pDJVECTURA : Initiates Legal Proceedings Against GSK
05:01pDJGLAXOSMITHKLINE : Helped and Hurt by Sterling's Post-Brexit Fall
03:02pDJBAYER : Reports Higher Second-Quarter Profit, Raises Guidance -- 2nd Update
02:33pDJGLAXOSMITHKLINE : Glaxo Swings to Loss on Write-Down But Core Earnings, Revenue ..
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
11:13a BIOTECH DAILY DIGEST : Gilead's Thud, Tobira Gets A Shout-Out, Spotlight On Adva..
07/25 BIOTECH FORUM DAILY DIGEST : Will Biotech Finally Break Out? All Eyes On Gilead,..
07/25 Is Biotech Finally Ready To Move Higher?
07/23 Biogen Q2 Plusses And Minuses
07/23 It's The Volatility, Stupid
Advertisement
Financials ($)
Sales 2016 11 438 M
EBIT 2016 5 875 M
Net income 2016 4 022 M
Finance 2016 1 458 M
Yield 2016 -
P/E ratio 2016 15,70
P/E ratio 2017 14,60
EV / Sales 2016 5,37x
EV / Sales 2017 5,24x
Capitalization 62 896 M
More Financials
Chart BIOGEN INC
Duration : Period :
Biogen Inc Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Full-screen chart
Technical analysis trends BIOGEN INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 333 $
Spread / Average Target 16%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
George A. Scangos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Spyridon Artavanis-Tsakonas Chief Scientific Officer & Executive VP
Adriana Karaboutis Executive VP-Technology & Business Solutions
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC-6.30%62 896
ABBVIE INC8.79%104 239
MERCK KGAA9.43%13 929
KYOWA HAKKO KIRIN CO L..0.58%10 467
JAZZ PHARMACEUTICALS P..-1.17%8 403
MALLINCKRODT PLC-10.41%7 310
More Results